Click on a filter below to refine your search. Remove a filter to broaden your search.
Metformin displayed a lowest risk for dementia across diverse antidiabetics, while α-glucosidase inhibitors had the highest risk.
Some of the factors include social isolation, diabetes, heart disease, vitamin D deficiency, high C-reactive protein and low handgrip strength.
The findings persisted across age, sex and comorbidities.
The reduction in risk was greatest for those with a history of ischemic heart disease or stroke.
SGLT-2is are associated with the lowest probability for adverse outcomes followed by glucagon-like peptide-1 receptor agonists and metformin.
Sulfonylurea monotherapy was linked to increased risk for all-cause dementia compared with metformin monotherapy.